The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program

Related Resources
All Resources

case-study
Partnership helped to reduce time to market by ensuring for U.S. based virtual Biopharmaceutical company
Read More

case-study
Process improvements and in-person monitoring help U.S. pharmaceutical company achieve on time for Phase III clinical trials
Read More

post
Exploring Risk-Based Approaches to Raw Material Testing in Pharmaceutical Manufacturing
Read More

post
Potency Assurance for Cellular and Gene Therapy Products
Read More
Let's move from science to success.
Let’s Talk